Concepedia

Fumitaka Suto

FS

16

Publications

400

Citations

13

H-Index

2009

Active since

Affiliations

Daiichi Sankyo (United States)(Current)

Daiichi-Sankyo (Japan)

Ono Pharmaceutical (Japan)

Shikoku Cancer Center

Kindai University Hospital

Fumitaka Suto is an author at Daiichi Sankyo (United States) specializing in medicine, radiation oncology, and cancer therapeutics.

ORCID

Top concepts

Publications per year

2009–2024

16

Publications

16

Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial

Kohei Shitara, Yung‐Jue Bang, Satoru Iwasa et al. · Nature Medicine · 2024 · 74 citations · Full text

IOP-Lowering Effect of ONO-9054, A Novel Dual Agonist of Prostanoid EP3 and FP Receptors, in Monkeys

Shinsaku Yamane, Tomohiro Karakawa, Satoshi Nakayama et al. · Investigative Ophthalmology & Visual Science · 2015 · 42 citations

162O Primary analysis from DS8201-A-U105: A 2-part, open label, phase Ib trial assessing trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing advanced breast cancer

E.P. Hamilton, Charles L. Shapiro, Valentina Boni et al. · Annals of Oncology · 2022 · 36 citations

, , +8

Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study

Erika Hamilton, Matthew D. Galsky, Sebastian Ochsenreither et al. · Clinical Cancer Research · 2024 · 31 citations · Full text

HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer

Ansh Kapil, Andreas Spitzmüller, Nicolas Brieu et al. · Scientific Reports · 2024 · 29 citations · Full text

Rows per page

1–5 of 16